Dongrui Pharmaceutical: Subsidiary Suzhou Dongrui Pharmaceutical Co., Ltd. has obtained the drug manufacturing registration approval for Sitagliptin Succinate Tablets.

Dongrui Pharmaceutical Announcement: The group’s subsidiary, Suzhou Dongrui Pharmaceutical Co., Ltd., is the second domestic company to obtain drug manufacturing registration approval from the China National Medical Products Administration for Quglutide Succinate Tablets 50 mg and 100 mg. It belongs to Category 3 chemical drugs and is deemed to have passed the consistency evaluation. This product is an oral weekly hypoglycemic preparation. It can be used as monotherapy for adult patients with type 2 diabetes to improve blood glucose control.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pinned